Does NMN Actually Work? What 2025 Human Trials Say About NMN and NR for Longevity

If you follow longevity science at all, you have encountered NMN. Nicotinamide mononucleotide — along with its close cousin nicotinamide riboside (NR) — became the flagship supplement of a new category: NAD+ precursors. The promise is elegant: NAD+ declines with age, NAD+ is essential for cellular energy metabolism, DNA repair, and sirtuins (the so-called longevity proteins), so taking a precursor that raises NAD+ should slow aging.

David Sinclair, the Harvard longevity researcher who co-authored the landmark 2013 paper linking NAD+ decline to aging, disclosed publicly that he takes NMN daily. He is far from alone. NMN became a multi-hundred-million dollar supplement category, with prices ranging from $40 to over $150 per month depending on brand and dose.

The mechanism is real. The animal data is real. The commercial demand is very real. But as of 2025, the human evidence has a significant gap: taking NMN or NR reliably raises blood NAD+ levels — and then, in most well-designed human trials, not much else clearly happens.

This article reviews what the human evidence actually shows across the domains that matter most for longevity: muscle mass and strength, metabolic markers, cognitive function, and biological aging. The findings are more nuanced than either the enthusiasts or the skeptics suggest — but they are substantially weaker than the marketing implies.

To evaluate the clinical evidence fairly, it helps to understand what these compounds do mechanistically — and where the theory gets complicated.

NAD+ (nicotinamide adenine dinucleotide) is a cofactor involved in hundreds of enzymatic reactions, including the electron transport chain that produces cellular energy (ATP), the sirtuin family of deacylases (SIRT1–SIRT7) that regulate gene expression and stress responses, PARP enzymes that repair DNA strand breaks, and CD38, an enzyme involved in immune function and calcium signaling.

NAD+ levels decline with age in humans — this is well-established. The decline appears to be driven partly by increased consumption (more DNA damage, inflammation, and metabolic stress that consumes NAD+) and partly by changes in biosynthesis. Raising NAD+ levels in aged mice through NMN or NR supplementation has produced striking results in animal models: improved muscle function, better cardiovascular performance, extended lifespan in some strains, and protection against metabolic disease.

**NMN versus NR: the practical difference.** Both are NAD+ precursors. NR (nicotinamide riboside) is converted to NMN in cells, which is then converted to NAD+. NMN can be converted to NR during intestinal absorption, making the two pathways partially overlapping. In pharmacokinetic studies, both compounds reliably and dose-dependently raise blood NAD+ levels in humans — this is the one finding that is consistent and replicated. The controversy is whether raising blood NAD+ translates to meaningful functional improvements in the tissues that matter for aging.

The gap between 'NAD+ goes up in blood' and 'aging-relevant function improves' is where the clinical evidence gets complicated. Blood NAD+ may not reflect intracellular NAD+ in metabolically important tissues like muscle, brain, and liver — and the animal data suggesting dramatic lifespan extension was generated in mice, where NAD+ biology and aging timescales are very different from humans.

The most comprehensive human evidence assessment as of 2025 comes from a systematic review and meta-analysis published in PMC (PMC12022230) covering the effect of NMN and NR on skeletal muscle mass and function in older adults. This is arguably the most longevity-relevant functional domain: muscle mass and function are among the strongest predictors of healthspan and mortality in aging populations.

The researchers searched PubMed, Cochrane Library, Web of Science, and Scopus, identifying randomized controlled trials comparing NMN or NR versus placebo. The analysis included participants with a mean age range of 60.9 to 83 years across multiple trials — the age group where NAD+ decline is most pronounced and where the intervention would be expected to have the most impact.

**The results across every muscle-related outcome were null:**

**Skeletal muscle index (SMI):** NMN supplementation showed no significant effect (n=3 trials, mean difference −0.42, 95% CI −0.99 to 0.14, p=0.14). Not statistically significant.

**Handgrip strength:** No significant effect (n=5 trials, mean difference 0.61 kg left grip, 95% CI −0.89 to 2.10, p=0.42; similar null finding for right grip). Not statistically significant.

**Gait speed:** No significant effect (n=4 trials, mean difference −0.01 m/s, 95% CI −0.08 to 0.06, p=0.79). Not statistically significant.

**5-Time Chair Stand Test:** No significant effect (n=2 trials, mean difference −0.21 seconds, 95% CI −0.70 to 0.29, p=0.41).

The narrative synthesis for additional outcomes (knee extension strength, Short Physical Performance Battery, thigh muscle mass) showed consistent null results for NMN. For NR specifically, one trial found improved 6-minute walking distance in peripheral artery disease patients — a positive signal in a specific pathological condition — but NR was associated with worse SPPB scores and slower chair stand times in mild cognitive impairment. No clear positive signal for NR in generally healthy older adults.

The conclusion from the meta-analysis authors: 'Current evidence does not support the use of NMN and NR as effective interventions for improving muscle function and mass in adults above 60 years old.'

This is a significant finding. If NMN and NR cannot improve muscle mass or function in the population with the greatest NAD+ deficit, using them primarily as anti-aging interventions requires a different evidence argument — one that does not currently exist in the peer-reviewed literature.

The picture for metabolic outcomes is slightly more nuanced — but still falls well short of the claims made in supplement marketing.

A 2024 systematic review and meta-analysis published in Tandfonline (also indexed on PubMed, PMID 39116016) examined the effect of oral NMN supplementation on glucose and lipid metabolism across 12 studies with 513 participants.

**The consistent finding:** NMN supplementation significantly elevated blood NAD+ levels across trials. This confirms that oral NMN reaches the bloodstream and raises the target biomarker — proof of concept for the delivery mechanism.

**The inconclusive findings for clinical outcomes:** Effects on glucose metabolism and lipid markers were inconsistent across trials. The meta-analysis identified evidence of publication bias in triglyceride outcomes using Egger's regression test — indicating that negative or null results may be underrepresented in the published NMN literature, which would inflate the apparent efficacy signals.

**The earlier 2022 RCT benchmark:** The Yoshino et al. trial published in Science (n=25 postmenopausal women with prediabetes or overweight, 10 weeks of 250 mg NMN daily) showed improved muscle insulin signaling — a mechanistically interesting finding. However, this was a small trial, used a specific population, and the improvements were in signaling pathways rather than clinical metabolic outcomes like fasting glucose, HbA1c, or body composition.

Taken together: NMN raises NAD+ reliably. Metabolic improvements are possible in specific contexts but inconsistent and, given publication bias concerns, probably smaller than the published literature suggests.

One of the highest-quality recent NR trials examined its use in long-COVID, published in eClinicalMedicine (The Lancet's open-access journal) in November 2025.

The trial enrolled participants with long-COVID experiencing cognitive symptoms — a population with measurable baseline NAD+ deficiency — and supplemented with NR. The primary finding: NR significantly increased blood NAD+ levels within 5 weeks. Mechanistically, the intervention worked exactly as intended.

The functional outcomes were sobering: NR did not significantly improve cognition, fatigue, sleep, or mood compared to placebo at the primary endpoint. Exploratory analyses suggested some within-group benefits after 10 weeks, but these are hypothesis-generating rather than confirmatory.

The Lancet authors concluded that 'larger trials are needed.' This is researcher language for: we saw a hint of something but cannot claim it confidently on this data.

What makes this trial informative for the general NMN/NR question is the pattern: blood NAD+ goes up clearly and consistently, and the functional outcomes do not follow in lockstep. This is the core problem with the NAD+ supplementation evidence base — the biomarker (blood NAD+) responds, but the clinical outcomes that matter for aging are not reliably responding in well-designed human trials.

Not all the 2025 NR news was null. ScienceDaily reported in December 2025 on a landmark clinical trial from Chiba University: the world's first rigorous clinical trial of NR in patients with Werner syndrome (WS), published in Aging Cell on June 3, 2025.

Werner syndrome is a rare genetic disorder causing dramatically accelerated aging — patients develop gray hair, cataracts, diabetes, and skin ulcers typically from their twenties. The Chiba team, working with Vilhelm Bohr from University of Copenhagen, showed that WS patients have depleted NAD+ levels, and that NR supplementation in this population produced measurable benefits in this pilot randomized, double-blind, placebo-controlled trial.

This is a genuinely positive finding — but the key word is 'Werner syndrome.' WS is a monogenic disease with a known, severe NAD+ depletion mechanism. The results in this ultra-rare disease population do not straightforwardly generalize to generally healthy adults taking NMN for preventive longevity purposes. The findings do strengthen the mechanistic argument that NAD+ depletion causes aging phenotypes — but they do not close the gap between 'NAD+ depletion causes aging' and 'supplementing NAD+ in people who are not severely depleted reverses aging.'

Think of it this way: the fact that giving vitamin C to people with scurvy cures scurvy does not mean that people who already consume adequate vitamin C will live longer by taking more vitamin C. The dose-response and the mechanistic logic differ between deficiency states and supplementation in replete individuals.

Given the 2025 evidence landscape, here is what it is reasonable to say about NMN and NR:

**Reliably demonstrated in humans:** Oral NMN and NR raise blood NAD+ levels in a dose-dependent manner. This is consistent across trials. If your goal is to raise a blood marker, both compounds accomplish it.

**Not demonstrated at scale in humans:** Improvements in muscle mass, muscle strength, or physical function in older adults (direct null finding across 10 RCTs). Consistent improvements in glucose, insulin sensitivity, or lipid profiles in the general population. Cognitive improvement in long-COVID (Lancet NR trial primary endpoint missed).

**Plausible but not confirmed:** Benefit in specific NAD+-depleted clinical populations (Werner syndrome data is promising). Potential for metabolic benefit in individuals with documented NAD+ deficiency or severe metabolic dysfunction. Longer-term effects not yet captured in the 4–24 week trial windows used in most human studies.

**Where the evidence gap lives:** Almost all human RCTs have been 4–24 weeks in duration. Longevity effects by definition operate over years to decades. The most compelling animal data showed lifespan extension with long-term supplementation — and no human trial has come close to capturing that timescale. This does not make NMN/NR useless; it means the human evidence base is immature relative to the longevity claims being made.

**The funding question:** Unlike collagen (where independent funding status is a major predictor of study outcome), the NMN literature has a mix of funding sources. The publication bias concerns in the metabolic meta-analysis are worth noting — they suggest the published positive signals may be inflated — but the NMN evidence situation is not as stark a funding-source split as in collagen.

**Safety:** Across completed trials, NMN and NR have a clean safety profile. Doses up to 1,200–2,000 mg/day have been tested without serious adverse events. This is well-established. The question is entirely efficacy, not safety.

The honest framing is that NMN and NR occupy a specific tier in the evidence hierarchy: mechanistically plausible, robustly supported in animal models, safe in humans, and currently unconfirmed for the functional aging outcomes that matter most in adequately powered human trials.

This puts them in a different category from the supplements with the strongest human evidence for longevity-relevant outcomes: creatine (multiple RCTs showing muscle mass, cognitive, and metabolic benefits — see /blog/creatine-for-longevity-evidence-and-safety), omega-3 EPA/DHA (decades of cardiovascular outcome data — see /blog/omega-3-epa-dha-longevity-dosing), and urolithin A (Nature Aging-published RCT data on mitophagy and muscle aging — see /blog/urolithin-a-longevity-guide).

It also puts them in a different category from the clearly oversold supplements where independent evidence is substantially weaker than marketed: collagen for skin aging (see /blog/collagen-peptides-aging-evidence), taurine for longevity (the 2023 Science correlation failed to replicate — see /blog/taurine-longevity-evidence-2025), and resveratrol (clinical trials have been consistently disappointing).

NMN and NR sit in the middle: better mechanism than most supplements, better safety data than most, and weaker efficacy confirmation than the marketing implies.

**Practical guidance for stack decisions:**

If you are building a longevity supplement stack from scratch and budget is a consideration, prioritize the evidence-confirmed foundations first: creatine, omega-3s, magnesium, vitamin D (if deficient), and urolithin A. These have stronger human evidence for functional outcomes than NMN or NR.

If you are already hitting the evidence-confirmed foundations and want to add an experimental layer, NMN or NR are reasonable choices — provided you understand you are making a bet on mechanism and animal data rather than confirmed human functional outcomes.

If you are in a higher-risk group for NAD+ depletion — family history of metabolic disease, documented insulin resistance, or a serious genetic condition affecting NAD+ metabolism — the case for NAD+ precursors is somewhat stronger, and discussing it with a clinician makes sense.

Track biological age markers before and after any supplementation protocol to get personal signal. See /blog/biological-age-testing-guide for the testing approaches most sensitive to lifestyle and supplement interventions.

**Does NMN actually increase NAD+ levels in humans?** Yes, consistently. Oral NMN and NR supplementation dose-dependently raises blood NAD+ levels across multiple human trials. This is one of the most replicated findings in the NAD+ supplementation literature. The question is whether that blood NAD+ increase translates to functional benefits in the tissues and pathways that matter for aging.

**What dose of NMN is used in human trials?** Most trials use 250–1,000 mg/day. The largest RCT to date tested 300, 600, and 1,200 mg doses. Higher doses produce larger NAD+ increases. Effects on functional outcomes remain inconsistent regardless of dose in published trials.

**Is NMN or NR better for longevity?** Both convert to NAD+ through slightly different pathways. NR is converted to NMN in cells before becoming NAD+. NMN may be partially converted to NR during gut absorption. In practice, both raise blood NAD+ effectively. The clinical evidence base for NMN is somewhat larger than for NR in healthy adults. Neither has demonstrated clear superiority for longevity-relevant outcomes in head-to-head human trials.

**What did David Sinclair find wrong with NMN evidence?** Sinclair continues to take NMN personally based on the mechanistic theory and his interpretation of animal data. His public stance is that the human trial durations have been too short to capture longevity effects and that the biomarker (NAD+ increase) is a reasonable target. The meta-analyses as of 2025 have not confirmed functional benefits in healthy older adults — which represents a meaningful gap between the mechanistic hypothesis and the human evidence.

**Is NMN safe to take long-term?** Based on available trial data — mostly up to 24 weeks — yes, NMN and NR have a clean safety profile. No serious adverse events have been reported in clinical trials at typical supplemental doses. The 2022 multicenter Japanese dose-escalation trial (PMID 36482258) tested doses up to 1,200 mg/day and found no significant safety concerns.

**Should I take NMN if I am under 50?** The evidence case is weakest for younger, healthier adults where NAD+ decline is less severe. The existing trials enrolled predominantly older adults (60+) where the NAD+ deficit is greatest — and even in that population, functional benefits were not confirmed. For adults under 50, the evidence case for NMN is speculative rather than even preliminary.

**What should I measure to know if NMN is working?** Blood NAD+ testing is available through some longevity clinics — it will likely go up, confirming delivery. For functional outcomes that matter, track biological age markers (DunedinPACE, GrimAge), muscle function (grip strength, gait speed), and metabolic markers (fasting glucose, insulin, HbA1c) before and after a 12-week minimum protocol. See /blog/biological-age-testing-guide for the testing methods.

Take the AliveLongevity healthspan quiz at /quiz/healthspan to get a personalized supplement priority framework based on your current protocol, age, and health goals. NMN and NR are included in the framework with their current evidence tier clearly labeled. **Disclaimer:** AliveLongevity content is educational and does not constitute medical advice. NMN and NR are not FDA-approved to treat, prevent, or reverse any disease. This article reflects published research as of March 2026. Consult a qualified clinician before starting any new supplement protocol.